search
Back to results

Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye

Primary Purpose

Dry Eye Syndromes

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Botulinum toxin type A injection
Saline solution injection
Sponsored by
Instituto de Oftalmología Fundación Conde de Valenciana
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dry Eye Syndromes focused on measuring Dry eye, Botulinum toxin A, Orbicularis muscle of the eye

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein.

Exclusion Criteria:

  • Dry eye patients attributable to abnormalities of the eyelids (problems with the mechanism of blinking, poor eyelid position, changes in position or structure of the eyelashes, high surface lesions, etc.)
  • Nasolacrimal obstruction.
  • Active corneal infection.
  • Patients with severe grade 4 dry eye.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Sham Comparator

    Arm Label

    Botulinum toxin type A injection

    Sham injection

    Arm Description

    An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.

    An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.

    Outcomes

    Primary Outcome Measures

    Symptoms of dry eye (questionnaire)
    A questionnaire assessing symptoms of dry eye each eye separately, including dryness, watery eyes, itching, burning, foreign body, fluctuating vision and light sensitivity. Depending on the frequency, each symptom will be graded from 0 to 5.
    Symptoms of conjunctivitis (questionnaire)
    A questionnaire assessing symptoms of conjunctivitis eye separately, including redness and discharge. Depending on the frequency, each symptom will be graded from 0 to 5.
    Quality of vision (graded perception of patient)
    The quality of vision will be graded from 0 to 5 according to the perception of the patient.
    Ocular comfort level (graded perception of patient)
    The ocular comfort level will be graded from 0 to 5 according to the perception of the patient.
    Moisturizing agent usage (patient will be asked how many times a day does he use the moisturizing agent and will be graded from 0 to 5 according to the frequency)
    The
    Visual acuity (Snellen vision acuity)
    Snellen vision acuity
    Measurement of the tear film break up time (After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking)
    After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking will be recorded in seconds.
    Schirmer's test
    After instillation of topical anesthetic, paper strips are inserted into the conjunctival sac for 5 minutes to measure the production of tears in millimeters.
    Oxford grading scheme for corneal and conjunctival staining
    After fluorescein staining, the corneal and conjunctival staining will be graded according to severity from 0 to 5.

    Secondary Outcome Measures

    Full Information

    First Posted
    January 21, 2015
    Last Updated
    March 30, 2015
    Sponsor
    Instituto de Oftalmología Fundación Conde de Valenciana
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02403219
    Brief Title
    Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye
    Official Title
    Paralysis of the Orbicularis Muscle of the Eye by Using Botulinum Toxin Type A in the Treatment for Dry Eye
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    May 2013 (undefined)
    Primary Completion Date
    February 2014 (Actual)
    Study Completion Date
    January 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Instituto de Oftalmología Fundación Conde de Valenciana

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This is a prospective, comparative, contralateral eye study. Patients older than 18 years who have had treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein were included. Patients with dry eye attributable to abnormalities of the eyelids, nasolacrimal obstruction and active corneal infection, as well as patients with severe dry eye were excluded from the study. One eye randomly received a subcutaneous injection of botulinum toxin in the medial part of the lower eyelid, and the other eye received a similar procedure with placebo. The subjective evaluation was achieved with a questionnaire assessing symptoms of dry eye and conjunctivitis, quality of vision and ocular comfort level each eye separately. The objective evaluation included the measurement of the tear film break up time, Schirmer's test and with a modification of the Oxford grading scheme for corneal and conjunctival staining.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Dry Eye Syndromes
    Keywords
    Dry eye, Botulinum toxin A, Orbicularis muscle of the eye

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    Participant
    Allocation
    Non-Randomized
    Enrollment
    20 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Botulinum toxin type A injection
    Arm Type
    Experimental
    Arm Description
    An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
    Arm Title
    Sham injection
    Arm Type
    Sham Comparator
    Arm Description
    An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
    Intervention Type
    Drug
    Intervention Name(s)
    Botulinum toxin type A injection
    Other Intervention Name(s)
    Botox
    Intervention Description
    Injection of botulinum toxin type A
    Intervention Type
    Other
    Intervention Name(s)
    Saline solution injection
    Other Intervention Name(s)
    Saline solution
    Intervention Description
    Injection of saline solution
    Primary Outcome Measure Information:
    Title
    Symptoms of dry eye (questionnaire)
    Description
    A questionnaire assessing symptoms of dry eye each eye separately, including dryness, watery eyes, itching, burning, foreign body, fluctuating vision and light sensitivity. Depending on the frequency, each symptom will be graded from 0 to 5.
    Time Frame
    6 months
    Title
    Symptoms of conjunctivitis (questionnaire)
    Description
    A questionnaire assessing symptoms of conjunctivitis eye separately, including redness and discharge. Depending on the frequency, each symptom will be graded from 0 to 5.
    Time Frame
    6 months
    Title
    Quality of vision (graded perception of patient)
    Description
    The quality of vision will be graded from 0 to 5 according to the perception of the patient.
    Time Frame
    6 months
    Title
    Ocular comfort level (graded perception of patient)
    Description
    The ocular comfort level will be graded from 0 to 5 according to the perception of the patient.
    Time Frame
    6 months
    Title
    Moisturizing agent usage (patient will be asked how many times a day does he use the moisturizing agent and will be graded from 0 to 5 according to the frequency)
    Description
    The
    Time Frame
    6 months
    Title
    Visual acuity (Snellen vision acuity)
    Description
    Snellen vision acuity
    Time Frame
    6 months
    Title
    Measurement of the tear film break up time (After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking)
    Description
    After fluorescein staining, the time required for dry spots to appear on the corneal surface after blinking will be recorded in seconds.
    Time Frame
    6 months
    Title
    Schirmer's test
    Description
    After instillation of topical anesthetic, paper strips are inserted into the conjunctival sac for 5 minutes to measure the production of tears in millimeters.
    Time Frame
    6 months
    Title
    Oxford grading scheme for corneal and conjunctival staining
    Description
    After fluorescein staining, the corneal and conjunctival staining will be graded according to severity from 0 to 5.
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein. Exclusion Criteria: Dry eye patients attributable to abnormalities of the eyelids (problems with the mechanism of blinking, poor eyelid position, changes in position or structure of the eyelashes, high surface lesions, etc.) Nasolacrimal obstruction. Active corneal infection. Patients with severe grade 4 dry eye.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Juan Carlos Serna-Ojeda, MD
    Organizational Affiliation
    Instituto de Oftalmologia Conde de Valenciana
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Ángel Nava-Castañeda, MD
    Organizational Affiliation
    Instituto de Oftalmologia Conde de Valenciana
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    17508116
    Citation
    The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2):75-92. doi: 10.1016/s1542-0124(12)70081-2.
    Results Reference
    background
    PubMed Identifier
    12488263
    Citation
    Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003 Jan;87(1):54-6. doi: 10.1136/bjo.87.1.54.
    Results Reference
    background
    PubMed Identifier
    10764857
    Citation
    Sahlin S, Chen E, Kaugesaar T, Almqvist H, Kjellberg K, Lennerstrand G. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000 Apr;129(4):481-6. doi: 10.1016/s0002-9394(99)00408-0.
    Results Reference
    background
    PubMed Identifier
    8890438
    Citation
    Reifler DM. Early descriptions of Horner's muscle and the lacrimal pump. Surv Ophthalmol. 1996 Sep-Oct;41(2):127-34. doi: 10.1016/s0039-6257(96)80002-6.
    Results Reference
    background
    PubMed Identifier
    15808266
    Citation
    Kakizaki H, Zako M, Miyaishi O, Nakano T, Asamoto K, Iwaki M. The lacrimal canaliculus and sac bordered by the Horner's muscle form the functional lacrimal drainage system. Ophthalmology. 2005 Apr;112(4):710-6. doi: 10.1016/j.ophtha.2004.11.043.
    Results Reference
    background

    Learn more about this trial

    Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye

    We'll reach out to this number within 24 hrs